21st Annual Norwegian Symposium on Heart Research
Mavacamten is a cardiac myocin-ATPase inhibitor targeted at treating hypertrophic cardiomyopathy (HCM). It has shown great results in reducing symptoms and improving hemodynamics in obstructive HCM patients. It is approved for use and is now recommended by new ESC Cardiomyopathy Guidelines 2023 for treatment of obstructive HCM.
The 21st Annual Norwegian Symposium on Heart Research, organized by Department of Cardiology, Oslo University Hospital in collaboration with ProCardio and Norheart, took place at the end of August, lining up tightly after European Society of Cardiology Congress with its final day on the 28th. The expressive frame of Holmenkollen hosted a consistent group of young and senior cardiologists, researchers and PhD students, who presented their projects during the abstract sessions. Four fellows from ProCardio displayed their work with abstracts on three different topics, including “Genetics and arrhythmias", “Cardiac function" and “Exercise and prevention".
During the sessions, Isotta Castrini presented the results of a study on the association between atrial cardiomyopathy and atrial fibrillation in Lamin A/C cardiomyopathy. Christian Five presented his results about the association between lifetime exercise dose and ventricular arrhythmias in arrhythmic mitral valve prolapse. Marianne Forså presented findings from a study comparing the development of athlete's heart with the early stage of hypertrophic cardiomyopathy in youth.
Jorun Tangen presented her project about the prognostic role of dilated left atrium volume in patients with myocardial infarction. She also displayed earlier findings of this study at the American Society of Echocardiography (ASE) Congress in Maryland, Washington D.C on Saturday 24th of June.